Cipla Ltd signed definitive agreements to acquire a 100% stake in Inzpera Healthsciences Ltd for a total consideration of approximately ₹110.65 crore. After the transaction closes, Cipla will operate Inzpera as a wholly owned subsidiary.
Transaction Details
Cipla will complete the ₹120-crore cash acquisition, subject to standard closing adjustments, and expects to conclude the deal within a month of signing the transaction documents.
Strategic Rationale
Cipla stated that the acquisition aligns with its strategy to strengthen its presence in the paediatric and wellness portfolio. As reported by cnbctv18.com, the company aims to expand market reach and scale by combining Inzpera’s paediatric formulations with Cipla’s distribution network and operational expertise.
